Boston Scientific wins $27bn bid for Guidant
In an effort to top rival Johnson & Johnson's recent $21.5bn offer, Boston Scientific Corp. has made its own cash and stock bid for Guidant. BSC has proposed $72 per share ($36 in cash and $36 in stock) for each Guidant outstanding share, valuing the deal at about $25bn, a 14% premium to J&J's offer. J&J bid $76 per share for the company a year ago and has revised its offer several times, the latest being $63.43 per share.
- Medical Devices
- Site Specific
- Drug Delivery
- Implantable Devices
- Surgical Equipment & Devices
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.